/
•
•
The US health regulator, in a letter to the pharma company, accuses it of violating good manufacturing practices at its Vadodara plant.

Once a stock market darling, the pharma company is bearing the brunt of a costly acquisition.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.